Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Cash from Investing Activities came in at -$1.1 billion in Q2 2026, up 93.92% year-over-year from -$572.4 million in Q2 2025, and down 6.73% quarter-over-quarter from -$1.0 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Cash from Investing Activities across 18 years of filings, most recently posting -$1.1 billion for Q2 2026.
- In Q2 2026, Cash from Investing Activities rose 93.92% year-over-year to -$1.1 billion; the TTM figure through Jun 2026 stood at -$7.2 billion (up 68.81% YoY), while the FY2025 annual figure was -$23.6 billion, down 26.82% from the prior year.
- Cash from Investing Activities came in at -$1.1 billion for Q2 2026 at Johnson & Johnson, down from -$1.0 billion in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $3.3 billion in Q2 2023 to a low of -$18.3 billion in Q2 2025.
- Average Cash from Investing Activities over 5 years is -$3.5 billion, with a median of -$1.3 billion recorded in 2023.
- Year-over-year, Cash from Investing Activities tumbled 1864.32% in 2022 and soared 191.22% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$3.6 billion in 2022, then surged by 66.92% to -$1.2 billion in 2023, then fell by 9.82% to -$1.3 billion in 2024, then tumbled by 239.77% to -$4.5 billion in 2025, then soared by 75.25% to -$1.1 billion in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$1.1 billion in Q2 2026, -$1.0 billion in Q1 2026, and -$4.5 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | -1.11 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | -1.20 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -5.60 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -3.11 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 2.11 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -1.61 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -424.26 Mn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | -1.66 Bn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | -49.35 Mn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | -51.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | -1.11 Bn |
| Mar 29, 2026 | -1.04 Bn |
| Dec 28, 2025 | -4.49 Bn |
| Sep 28, 2025 | -542.00 Mn |
| Jun 29, 2025 | -18.26 Bn |
| Mar 30, 2025 | -297.00 Mn |
| Dec 29, 2024 | -1.32 Bn |
| Sep 29, 2024 | -3.13 Bn |
| Jun 30, 2024 | -13.69 Bn |
| Mar 31, 2024 | -464.00 Mn |
| Dec 31, 2023 | -1.20 Bn |
| Oct 1, 2023 | 2.54 Bn |
| Jul 2, 2023 | -3.78 Bn |
| Apr 2, 2023 | 3.32 Bn |
| Jan 1, 2023 | -9.05 Bn |
| Apr 3, 2022 | -3.63 Bn |
| Oct 3, 2021 | -2.72 Bn |
| Jul 4, 2021 | -419.00 Mn |
| Apr 4, 2021 | -185.00 Mn |
| Jan 3, 2021 | -7.90 Bn |